Literature DB >> 207773

Thymopoietin enhances the allogeneic response and cyclic GMP levels of mouse peripheral, thymus-derived lymphocytes.

G H Sunshine, R S Basch, R G Coffey, K W Cohen, G Goldstein, J W Hadden.   

Abstract

The action of the purified thymic factor, thymopoietin, on populations of post-thymic lymphocytes has been studied. Thymopoietin, at concentrations as low as 1.5 ng/ml, uniquely enhanced the proliferative response of peripheral T cells from lymph node and spleen to allogeneic stimulation. Enhancement of the allogeneic response (MLR) was not produced by several polypeptide hormones, including insulin, ACTH, HCG, or Ubiquitin. Treatment of spleen cells with anti-Thy-1 antiserum almost completely abolished the MLR. Thymopoietin's stimulatory effects could not reverse this. Thymopoietin treatment of Thy-1+-enriched spleen cell populations enhanced the MLR even when thymopoietin was removed as early as 2 min after incubation with responding cells. The interaction of thymopoietin with peripheral Thy-1+ cell populations produced a rapid and transient rise in cyclic GMP levels and slightly decreased cyclic AMP levels. These results suggest that thymopoietin interacts with one or more Thy-1+ subpopulations and that this interaction involves early changes in cyclic nucleotide metabolism.

Entities:  

Mesh:

Substances:

Year:  1978        PMID: 207773

Source DB:  PubMed          Journal:  J Immunol        ISSN: 0022-1767            Impact factor:   5.422


  16 in total

Review 1.  Desensitization of the nicotinic acetylcholine receptor: molecular mechanisms and effect of modulators.

Authors:  E L Ochoa; A Chattopadhyay; M G McNamee
Journal:  Cell Mol Neurobiol       Date:  1989-06       Impact factor: 5.046

Review 2.  Immunomodulation with thymopentin: in vitro studies.

Authors:  J Duchateau; K Bolla
Journal:  Med Oncol Tumor Pharmacother       Date:  1989

3.  Three distinct human thymopoietins are derived from alternatively spliced mRNAs.

Authors:  C A Harris; P J Andryuk; S Cline; H K Chan; A Natarajan; J J Siekierka; G Goldstein
Journal:  Proc Natl Acad Sci U S A       Date:  1994-07-05       Impact factor: 11.205

4.  Arg-Lys-Asp-Val-Tyr (thymopentin) accelerates the cholinergic-induced inactivation (desensitization) of reconstituted nicotinic receptor.

Authors:  E L Ochoa; S Medrano; M C de Carlin; A M Dilonardo
Journal:  Cell Mol Neurobiol       Date:  1988-09       Impact factor: 5.046

5.  New approaches to immunotherapy: thymomimetic drugs.

Authors:  S Specter; J W Hadden
Journal:  Springer Semin Immunopathol       Date:  1985

6.  Prevention of recurrences in frequently relapsing herpes labialis with thymopentin. A randomized double-blind placebo-controlled multicenter study.

Authors:  K Bolla; D Djawari; E M Kokoschka; J Petres; S Lidén; R Gonseth; P Amblard; M G Bernengo; J J Bonerandi; A Claudy
Journal:  Surv Immunol Res       Date:  1985

7.  In vitro influence of thymopentin on proliferative responses and phytohemagglutinin-induced interleukin 2 production in normal human lymphocyte cultures.

Authors:  J Duchateau; G Servais; R Cooman; H Collet; K Bolla
Journal:  Surv Immunol Res       Date:  1985

8.  Rationale for thymopentin as therapeutic agent in rheumatoid arthritis.

Authors:  P Franchimont; K Bolla
Journal:  Surv Immunol Res       Date:  1985

9.  Isolation and complete amino acid sequence of human thymopoietin and splenin.

Authors:  T Audhya; D H Schlesinger; G Goldstein
Journal:  Proc Natl Acad Sci U S A       Date:  1987-06       Impact factor: 11.205

10.  The in vitro effect of the thymic factor thymopoietin on a subpopulation of lymphocytes from severely malnourished children.

Authors:  T M Jackson; S N Zaman
Journal:  Clin Exp Immunol       Date:  1980-03       Impact factor: 4.330

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.